Skip to content
2000
Volume 21, Issue 4
  • ISSN: 1573-398X
  • E-ISSN: 1875-6387

Abstract

Background

The world changed in December 2019 due to respiratory tract infection cases, initially of unknown etiology, later known as COVID-19.

Objective

This study aimed to determine the factors and comorbidities associated with mortality from COVID-19 in Mexico.

Methods

It was a cross-sectional and observational prospective study of patients treated at an IMSS (Mexican Institute of Social Security) Hospital in Morelos with a confirmed diagnosis of COVID-19. Logistic regression models and survival analyses were developed to identify factors associated with mortality risk.

Results

3,965 patients were analyzed, with most deaths occurring in men. The mortality risks were higher in men who were older than 50 years. The most significant associations were: age older than 80 years (HR:3.17), endotracheal intubation (HR:1.54), dyspnea (HR: 13.55), and polypnea (HR:1.54).

Conclusion

The risk of death in this population was high, considering the absence of primary protective measures at the beginning of the pandemic and the lack of consistency in using personal protection elements.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crmr/10.2174/011573398X336783250117111654
2025-01-22
2025-11-16

  • From This Site

    /content/journals/crmr/10.2174/011573398X336783250117111654
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Fricke-GalindoI. Falfán-ValenciaR. Genetics insight for covid-19 susceptibility and severity: A review.Front. Immunol.20211262217610.3389/fimmu.2021.62217633868239
     [Google Scholar]
  2. SharmaA. Ahmad FaroukI. LalS.K. COVID-19: A review on the novel coronavirus disease evolution, transmission, detection, control and prevention.Viruses202113220210.3390/v1302020233572857
     [Google Scholar]
  3. HuB. GuoH. ZhouP. ShiZ.L. Characteristics of SARS-CoV-2 and COVID-19.Nat. Rev. Microbiol.202119314115410.1038/s41579‑020‑00459‑733024307
     [Google Scholar]
  4. HuangC. WangY. LiX. RenL. ZhaoJ. HuY. ZhangL. FanG. XuJ. GuX. ChengZ. YuT. XiaJ. WeiY. WuW. XieX. YinW. LiH. LiuM. XiaoY. GaoH. GuoL. XieJ. WangG. JiangR. GaoZ. JinQ. WangJ. CaoB. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet20203951022349750610.1016/S0140‑6736(20)30183‑531986264
     [Google Scholar]
  5. LiQ. GuanX. WuP. WangX. ZhouL. TongY. RenR. LeungK.S.M. LauE.H.Y. WongJ.Y. XingX. XiangN. WuY. LiC. ChenQ. LiD. LiuT. ZhaoJ. LiuM. TuW. ChenC. JinL. YangR. WangQ. ZhouS. WangR. LiuH. LuoY. LiuY. ShaoG. LiH. TaoZ. YangY. DengZ. LiuB. MaZ. ZhangY. ShiG. LamT.T.Y. WuJ.T. GaoG.F. CowlingB.J. YangB. LeungG.M. FengZ. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia.N. Engl. J. Med.2020382131199120710.1056/NEJMoa200131631995857
     [Google Scholar]
  6. BogochI WattsA ThomasA HuberC KraemerM KhanK Pneumonia of unknown etiology in Wuhan, China: Potential for international spread via commercial air travel.J. Trav. Med.2020272taaa00810.1093/jtm/taaa008
     [Google Scholar]
  7. VincentJ.L. TacconeF.S. Understanding pathways to death in patients with COVID-19.Lancet Respir. Med.20208543043210.1016/S2213‑2600(20)30165‑X32272081
     [Google Scholar]
  8. WangW. TangJ. WeiF. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China.J. Med. Virol.202092444144710.1002/jmv.2568931994742
     [Google Scholar]
  9. BauchnerH. SharfsteinJ. A bold response to the COVID-19 pandemic: Medical students, national service, and public health.JAMA2020323181790179110.1001/jama.2020.616632267488
     [Google Scholar]
  10. SancheS. LinY.T. XuC. Romero-SeversonE. HengartnerN. KeR. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2.Emerg. Infect. Dis.20202671470147710.3201/eid2607.20028232255761
     [Google Scholar]
  11. World Health Organization Modes of transmission of virus causing COVID-19: Implications for IPC precaution recommendations. 2020Available from: https://www.who.int/ news-room/commentaries/detail/modes-of-transmission-of-virus-causingCovid-19-implications-for-ipc-precaution-recommendations
  12. LiuY. GuZ. XiaS. ShiB. ZhouX.N. ShiY. LiuJ. What are the underlying transmission patterns of COVID-19 outbreak? An age-specific social contact characterization.EClinicalMedicine20202210035410.1016/j.eclinm.2020.10035432313879
     [Google Scholar]
  13. LiY. WangJ.X. ChenX. Can a toilet promote virus transmission? From a fluid dynamics perspective.Phys. Fluids202032606510710.1063/5.001331832574232
     [Google Scholar]
  14. RothanH.A. ByrareddyS.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.J. Autoimmun.202010910243310.1016/j.jaut.2020.10243332113704
     [Google Scholar]
  15. Du ToitA. Outbreak of a novel coronavirus.Nat. Rev. Microbiol.202018312310.1038/s41579‑020‑0332‑031988490
     [Google Scholar]
  16. WangD. HuB. HuC. ZhuF. LiuX. ZhangJ. WangB. XiangH. ChengZ. XiongY. ZhaoY. LiY. WangX. PengZ. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.JAMA2020323111061106910.1001/jama.2020.158532031570
     [Google Scholar]
  17. ZhaoS. LinQ. RanJ. MusaS.S. YangG. WangW. LouY. GaoD. YangL. HeD. WangM.H. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak.Int. J. Infect. Dis.20209221421710.1016/j.ijid.2020.01.05032007643
     [Google Scholar]
  18. Parra-BracamonteG.M. Lopez-VillalobosN. Parra-BracamonteF.E. Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico.Ann. Epidemiol.2020529398.e210.1016/j.annepidem.2020.08.00532798701
     [Google Scholar]
  19. MunaycoC. ChowellG. TariqA. UndurragaE.A. MizumotoK. Risk of death by age and gender from CoVID-19 in Peru, March- May, 2020.Aging20201214138691388110.18632/aging.10368732692724
     [Google Scholar]
  20. AntonelliM. PenfoldR.S. MerinoJ. SudreC.H. MolteniE. BerryS. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: A prospective, community-based, nested, case-control study.Lancet Infect Dis.2022221435510.1016/S1473‑3099(21)00460‑6
     [Google Scholar]
  21. Brosh-NissimovT. Orenbuch-HarrochE. ChowersM. ElbazM. NesherL. SteinM. MaorY. CohenR. HusseinK. WeinbergerM. ZimhonyO. ChazanB. NajjarR. ZayyadH. RahavG. Wiener-WellY. BNT162b2 vaccine breakthrough: Clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel.Clin. Microbiol. Infect.202127111652165710.1016/j.cmi.2021.06.03634245907
     [Google Scholar]
  22. Hippisley-CoxJ. CouplandC.A.C. MehtaN. KeoghR.H. Diaz-OrdazK. KhuntiK. LyonsR.A. KeeF. SheikhA. RahmanS. ValabhjiJ. HarrisonE.M. SellenP. HaqN. SempleM.G. JohnsonP.W.M. HaywardA. Nguyen-Van-TamJ.S. Risk prediction of COVID-19 related death and hospital admission in adults after COVID-19 vaccination: National prospective cohort study.BMJ2021374n224410.1136/bmj.n224434535466
     [Google Scholar]
  23. McKeigueP. McAllisterD. RobertsonC. HutchinsonS. McGurnaghanS. StocktonD. Efficacy of two doses of COVID-19 vaccine against severe COVID-19 in those with risk conditions and residual risk to the clinically extremely vulnerable: The REACT-SCOT case-control study.medRxiv20212021.09.13.2126236010.1101/2021.09.13.21262360
     [Google Scholar]
  24. MeyerowitzE.A. RichtermanA. GandhiR.T. SaxP.E. Transmission of SARS-CoV-2: A review of viral, host, and environmental factors.Ann. Intern. Med.20211741697910.7326/M20‑500832941052
     [Google Scholar]
  25. DuR.H. LiangL.R. YangC.Q. WangW. CaoT.Z. LiM. GuoG.Y. DuJ. ZhengC.L. ZhuQ. HuM. LiX.Y. PengP. ShiH.Z. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: A prospective cohort study.Eur. Respir. J.2020555200052410.1183/13993003.00524‑202032269088
     [Google Scholar]
  26. NeriS. BarrancoG. LeónM. TovarS. RendónM. FloresM. Predictive factors of death in patients with influenza A H1N1 pneumonia.Med Int Mex.2011275421428
     [Google Scholar]
  27. Padilla-RaygozaN. Navarro-OlivosE. Gallardo-LunaM.J. Magos-VázquezF.J. Díaz-MartínezD.A. Sandoval-SalazarC. Díaz-BecerrilL.A. Clinical data, comorbidities, and mortality of COVID-19 in the state of guanajuato, mexico until may 20, 2020.Cent. Asian J. Glob. Health202091e52710.5195/cajgh.2020.52735866097
     [Google Scholar]
  28. HoffmannM. Kleine-WeberH. SchroederS. KrügerN. HerrlerT. ErichsenS. SchiergensT.S. HerrlerG. WuN.H. NitscheA. MüllerM.A. DrostenC. PöhlmannS. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.Cell20201812271280.e810.1016/j.cell.2020.02.05232142651
     [Google Scholar]
  29. LeungC. Risk factors for predicting mortality in elderly patients with COVID-19: A review of clinical data in China.Mech. Ageing Dev.202018811125510.1016/j.mad.2020.11125532353398
     [Google Scholar]
  30. YangJ. HuJ. ZhuC. Obesity aggravates COVID-19: A systematic review and meta-analysis.J. Med. Virol.202193125726110.1002/jmv.2623732603481
     [Google Scholar]
  31. SongJ. ZengM. WangH. QinC. HouH.Y. SunZ.Y. XuS.P. WangG.P. GuoC.L. DengY.K. WangZ.C. MaJ. PanL. LiaoB. DuZ.H. FengQ.M. LiuY. XieJ.G. LiuZ. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19.Allergy202176248349610.1111/all.1451732716553
     [Google Scholar]
  32. COVID-19 Guide for the care of critically ill patients with SARS- CoV-2 infection mexican college of critical care medicine.Crit. Care Med.202033174210.35366/93279
     [Google Scholar]
  33. WanY. ShangJ. SunS. TaiW. ChenJ. GengQ. HeL. ChenY. WuJ. ShiZ. ZhouY. DuL. LiF. Molecular mechanism for antibody-dependent enhancement of coronavirus entry.J. Virol.2020945e02015-1910.1128/JVI.02015‑1931826992
     [Google Scholar]
  34. ArentzM. YimE. KlaffL. LokhandwalaS. RiedoF.X. ChongM. LeeM. Characteristics and outcomes of 21  critically  ill  patients  with  COVID-19  in  Washington State.JAMA2020323161612161410.1001/jama.2020.432632191259
     [Google Scholar]
  35. Hernández-GaldamezD.R. González-BlockM.Á. Romo-DueñasD.K. Lima-MoralesR. Hernández-VicenteI.A. Lumbreras-GuzmánM. Méndez-HernándezP. Increased risk of hospitalization and death in patients with covid-19 and pre-existing noncommunicable diseases and modifiable risk factors in Mexico.Arch. Med. Res.202051768368910.1016/j.arcmed.2020.07.00332747155
     [Google Scholar]
  36. Martos-BenítezF.D. Soler-MorejónC.D. BarcoGD. Chronic comorbidities and clinical outcomes in patients with and without COVID-19: A large population-based study using national administrative healthcare open data of Mexico.Intern. Emerg. Med.20211661507151710.1007/s11739‑020‑02597‑533411264
     [Google Scholar]
  37. PeeplesL. Avoiding pitfalls in the pursuit of a COVID-19 vaccine.Proc. Natl. Acad. Sci. USA2020117158218822110.1073/pnas.200545611732229574
     [Google Scholar]
  38. FuY. ChengY. WuY. Understanding SARS-CoV-2-mediated inflammatory responses: From mechanisms to potential therapeutic tools.Virol. Sin.202035326627110.1007/s12250‑020‑00207‑432125642
     [Google Scholar]
  39. JinY. YangH. JiW. WuW. ChenS. ZhangW. DuanG. Virology, epidemiology, pathogenesis, and control of COVID-19.Viruses202012437210.3390/v1204037232230900
     [Google Scholar]
  40. LiuK. ChenY. LinR. HanK. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients.J. Infect.2020806e14e1810.1016/j.jinf.2020.03.00532171866
     [Google Scholar]
  41. KimT. Improving preparedness for and response to coronavirus disease 19 (COVID-19) in long-term care hospitals in Korea.Infect. Chemother.202052213314110.3947/ic.2020.52.2.13332406211
     [Google Scholar]
  42. YangX YuY XuJ ShuH XiaJ LiuH Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study.Lancet Respir Med.20208547548110.1016/S2213‑2600(20)30079‑5
     [Google Scholar]
  43. Bedolla-BarajasM. Morales-RomeroJ. Bedolla-PulidoT.R. Meza-LópezC. Robles-FigueroaM. Pulido-GuillénN.A. Orozco-AlatorreL.G. Andrade-CastellanosC.A. Low prevalence of asthma in Mexican children and adults with a positive rtRT-PCR test for SARS-CoV-2: A cross-sectional study during the 2020 pandemic.Allergol. Immunopathol.20214931710.15586/aei.v49i3.733938182
     [Google Scholar]
  44. Kammar-GarcíaA. Vidal-MayoJ.J. Vera-ZertucheJ.M. Lazcano- HernándezM. Vera-LópezO. Segura-BadillaO. Aguilar-AlonsoP. Navarro-CruzA.R. Impact of comorbidities in mexican SARS-CoV-2-positive patients: A retrospective analysis in a national cohort.Rev. Invest. Clin.202072315115810.24875/RIC.2000020732584330
     [Google Scholar]
  45. Bello-ChavollaO.Y. Bahena-LópezJ.P. Antonio-VillaN.E. Vargas-VázquezA. González-DíazA. Márquez-SalinasA. Fermín-MartínezC.A. NavejaJ.J. Aguilar-SalinasC.A. Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico.J. Clin. Endocrinol. Metab.202010582752276110.1210/clinem/dgaa34632474598
     [Google Scholar]
  46. JordanR.E. AdabP. ChengK.K. COVID-19: Risk factors for severe disease and death.BMJ2020368m119810.1136/bmj.m119832217618
     [Google Scholar]
  47. ZhengF. LiaoC. FanQ. ChenH. ZhaoX. XieZ. LiX. ChenC. LuX. LiuZ. LuW. ChenC. JiaoR. ZhangA. WangJ. DingX. ZengY. ChengL. HuangQ. WuJ. LuoX. WangZ. ZhongY. BaiY. WuX. JinR. Clinical characteristics of children with coronavirus disease 2019 in Hubei, China.Curr. Med. Sci.202040227528010.1007/s11596‑020‑2172‑632207032
     [Google Scholar]
  48. TagarroA. EpalzaC. SantosM. Sanz-SantaeufemiaF.J. OtheoE. MoraledaC. CalvoC. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain.JAMA Pediatr.2020e20134610.1001/jamapediatrics.2020.134632267485
     [Google Scholar]
  49. SawalhaA.H. ZhaoM. CoitP. LuQ. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients.Clin. Immunol.202021510841010.1016/j.clim.2020.10841032276140
     [Google Scholar]
  50. National center for immunization and respiratory diseases (NCIRD), division of viral diseases.2023Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
  51. DiazD.P. Description of COVID-19 mortality in three Latin American countries: Colombia, Argentina and Mexico 2020-2021.Available from: https://repository.javeriana.edu.co/handle/10554/ 64643
  52. Cepal - OPS The prolongation of the health crisis and its impact on health, the economy and social development.2021Available from: https://www.cepal.org/es/publicaciones/47301-la-prolongacion-la-crisis-sanitaria-su-impacto-la-salud-la-economia-desarrollo
  53. AbramsE.M. SzeflerS.J. COVID-19 and the impact of social determinants of health.Lancet Respir. Med.20208765966110.1016/S2213‑2600(20)30234‑432437646
     [Google Scholar]
  54. MenaG.E. MartinezP.P. MahmudA.S. MarquetP.A. BuckeeC.O. SantillanaM. Socioeconomic status determines COVID-19 incidence and related mortality in Santiago, Chile.Science20213726545eabg529810.1126/science.abg529833906968
     [Google Scholar]
  55. ZhangP. WeiM. JingP. LiZ. LiJ. ZhuF. COVID-19 in children: Epidemic issues and candidate vaccines.Chin. Med. J.2022135111314132410.1097/CM9.000000000000216935830254
     [Google Scholar]
  56. Najjar-DebbinyR. GronichN. WeberG. KhouryJ. AmarM. SteinN. GoldsteinL.H. SalibaW. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients.Clin. Infect. Dis.2023763e342e34910.1093/cid/ciac44335653428
     [Google Scholar]
  57. MirbeykM. SaghazadehA. RezaeiN. Geriatrics and COVID-19.Adv. Exp. Med. Biol.2021131820922210.1007/978‑3‑030‑63761‑3_1333973181
     [Google Scholar]
  58. SenkalN. BahatG. MedetalibeyogluA. CebeciT. DenizD. CatmaY. OrenM.M. CaparaliE.B. BayrakdarS. BasaranS. KoseM. ErelelM. KaranM.A. TukekT. Comparison of clinical characteristics and outcome measures of PCR-positive and PCR-negative patients diagnosed as COVID-19: Analyses focusing on the older adults.Exp. Gerontol.202217011199810.1016/j.exger.2022.11199836341785
     [Google Scholar]
  59. KalaiselvanP. YingchoncharoenP. ThongpiyaJ. MotesA. NugentK. COVID-19 infections and inflammatory markers in patients hospitalized during the first year of the pandemic.J. Prim. Care Community Health2023142150131923120691110.1177/2150131923120691137864436
     [Google Scholar]
  60. La-BeckN.M. LeeY.R. PatelJ. YangH. StoutM. KologeyA. RuesewaldA. AlvarezC.A. Clinical characteristics and patterns of immune responses in COVID-19 patients from a rural community hospital.Cureus2024166e6160010.7759/cureus.6160038962589
     [Google Scholar]
/content/journals/crmr/10.2174/011573398X336783250117111654
Loading
Risk factors for Mortality in Patients with COVID-19 in Cuernavaca- Morelos
Curr. Respir. Med. Rev. 21, 383 (2025); https://doi.org/10.2174/011573398X336783250117111654
/content/journals/crmr/10.2174/011573398X336783250117111654
/content/journals/crmr/10.2174/011573398X336783250117111654
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): COVID-19; Cuernavaca-Morelos; dyspnea; mortality; risk factors; SARS CoV-2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test